Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS.

Infect Immun. 2007 Aug;75(8):4173-80. Epub 2007 May 21.

2.

Pathogenesis of and immunity to melioidosis.

Brett PJ, Woods DE.

Acta Trop. 2000 Feb 5;74(2-3):201-10. Review.

PMID:
10674650
3.

Melioidosis vaccines.

Warawa J, Woods DE.

Expert Rev Vaccines. 2002 Dec;1(4):477-82. Review.

PMID:
12901586
4.

Development of Burkholderia mallei and pseudomallei vaccines.

Silva EB, Dow SW.

Front Cell Infect Microbiol. 2013 Mar 11;3:10. doi: 10.3389/fcimb.2013.00010. eCollection 2013. Review.

5.

Progress toward development of vaccines against melioidosis: A review.

Sarkar-Tyson M, Titball RW.

Clin Ther. 2010 Aug;32(8):1437-45. doi: 10.1016/j.clinthera.2010.07.020. Review.

PMID:
20728758
6.

Novel gain of function approaches for vaccine candidate identification in Burkholderia pseudomallei.

Dowling AJ.

Front Cell Infect Microbiol. 2013 Jan 9;2:139. doi: 10.3389/fcimb.2012.00139. eCollection 2012. Review.

7.

Consensus on the development of vaccines against naturally acquired melioidosis.

Limmathurotsakul D, Funnell SG, Torres AG, Morici LA, Brett PJ, Dunachie S, Atkins T, Altmann DM, Bancroft G, Peacock SJ; Steering Group on Melioidosis Vaccine Development.

Emerg Infect Dis. 2015 Jun;21(6). doi: 10.3201/eid2106.141480.

8.

Recent development in melioidosis.

Leelarasamee A.

Curr Opin Infect Dis. 2004 Apr;17(2):131-6. Review.

PMID:
15021053
9.

Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes.

Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day NP, Titball RW.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1488. doi: 10.1371/journal.pntd.0001488. Epub 2012 Jan 31. Review. Erratum in: PLoS Negl Trop Dis. 2013 Feb;7(2). doi:10.1371/annotation/20664ec9-17e4-4ba6-8c65-481a70a5c4ad.

10.

Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Bondi SK, Goldberg JB.

Expert Rev Vaccines. 2008 Nov;7(9):1357-65. doi: 10.1586/14760584.7.9.1357. Review.

11.

Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.

Aschenbroich SA, Lafontaine ER, Hogan RJ.

Expert Rev Vaccines. 2016 Sep;15(9):1163-81. doi: 10.1586/14760584.2016.1170598. Epub 2016 Apr 20. Review.

PMID:
27010618
12.

Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?

Titball RW, Burtnick MN, Bancroft GJ, Brett P.

Vaccine. 2017 Mar 20. pii: S0264-410X(17)30328-6. doi: 10.1016/j.vaccine.2017.03.022. [Epub ahead of print] Review.

PMID:
28336210
13.

What next for botulism vaccine development?

Webb RP, Smith LA.

Expert Rev Vaccines. 2013 May;12(5):481-92. doi: 10.1586/erv.13.37. Review.

PMID:
23659297
14.

Exploiting molecular virulence determinants in Burkholderia to develop vaccine antigens.

Casey WT, McClean S.

Curr Med Chem. 2015;22(14):1719-33. Review.

PMID:
25850766

Supplemental Content

Support Center